NEW YORK--(BUSINESS WIRE)--Regulatory News:
Cellectis (Paris:ALCLS) (NASDAQ:CLLS) (Alternext: ALCLS – Nasdaq Global Market: CLLS), a pioneering gene-editing company employing proprietary technologies to develop best-in-class products in the emerging field of immuno-oncology, today announced that pre-clinical data on its engineered allogeneic CAR T-cells will be featured during several conferences in the coming weeks.
Help employers find you! Check out all the jobs and post your resume.
